Ankit Mahadevia
2016
In 2016, Ankit Mahadevia earned a total compensation of $815K as Chief Executive Officer at Spero Therapeutics.
Compensation breakdown
| Bonus | $108,150 |
|---|---|
| Option Awards | $345,125 |
| Salary | $360,500 |
| Other | $1,210 |
| Total | $814,985 |
Mahadevia received $360.5K in salary, accounting for 44% of the total pay in 2016.
Mahadevia also received $108.2K in bonus, $345.1K in option awards and $1.2K in other compensation.
Rankings
In 2016, Ankit Mahadevia's compensation ranked 9,220th out of 14,075 executives tracked by ExecPay. In other words, Mahadevia earned more than 34.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,220 out of 14,075 | 35th |
Division Manufacturing | 3,558 out of 5,486 | 35th |
Major group Chemicals And Allied Products | 1,230 out of 1,900 | 35th |
Industry group Drugs | 975 out of 1,543 | 37th |
Industry Pharmaceutical Preparations | 773 out of 1,173 | 34th |
Source: SEC filing on April 27, 2018.
Mahadevia's colleagues
We found one more compensation record of an executive who worked with Ankit Mahadevia at Spero Therapeutics in 2016.
2016
Christina Larkin
Spero Therapeutics
Chief Operating Officer
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019